[Novel agents in multiple myeloma treatment]

Area of Science:

• Hematology
• Oncology
• Pharmacology

Context:

• Multiple myeloma (MM) remains incurable, necessitating novel therapeutic strategies.
• Bortezomib and immunomodulatory drugs (IMiDs) have improved MM patient outcomes.
• Second-generation IMiDs like pomalidomide are now available, offering new treatment options.

Purpose:

• To review emerging novel agents and treatment strategies for multiple myeloma.
• To highlight the efficacy of newer drugs in overcoming treatment resistance.
• To explore the potential of combination therapies for achieving durable remissions or cure.

Summary:

• Pomalidomide plus dexamethasone demonstrated significant advantages in Overall Response Rate (ORR), Progression-Free Survival (PFS), and Overall Survival (OS) in heavily pretreated MM patients (MM-003 trial).
• Carfilzomib combined with lenalidomide and dexamethasone showed a survival advantage in relapsed/refractory MM (ASPIRE trial).
• Novel agents including monoclonal antibodies (elotuzumab, daratumumab), second-generation proteasome inhibitors (carfilzomib), and others are under investigation.

Impact:

• These findings suggest that novel agents, used alone or in combination, can overcome double-refractory multiple myeloma.
• Investigating cocktails of agents with different mechanisms of action early in the disease course may lead to durable remissions or cure.
• Ongoing research into kinase inhibitors and signaling pathway inhibitors holds further promise for MM treatment.